Nexien Biopharma Stock Annual Yield
| NXEN Stock | USD 0.01 0.00 0.00% |
Nexien Biopharma fundamentals help investors to digest information that contributes to Nexien Biopharma's financial success or failures. It also enables traders to predict the movement of Nexien Pink Sheet. The fundamental analysis module provides a way to measure Nexien Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nexien Biopharma pink sheet.
Nexien |
Nexien Biopharma Company Annual Yield Analysis
Nexien Biopharma's Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.
Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.
| Competition |
In accordance with the recently published financial statements, Nexien Biopharma has an Annual Yield of 0.0%. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Idea Optimizer Now
Idea OptimizerUse advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
| All Next | Launch Module |
Nexien Fundamentals
| Return On Equity | -40.7 | |||
| Return On Asset | -5.99 | |||
| Current Valuation | 2.58 M | |||
| Shares Outstanding | 62.77 M | |||
| Shares Owned By Insiders | 54.17 % | |||
| Price To Book | 205.41 X | |||
| EBITDA | (563.99 K) | |||
| Net Income | (626.36 K) | |||
| Cash And Equivalents | 116.9 K | |||
| Total Debt | 221.73 K | |||
| Debt To Equity | 0.36 % | |||
| Current Ratio | 0.51 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (75.14 K) | |||
| Earnings Per Share | (0.01) X | |||
| Beta | 1.48 | |||
| Market Capitalization | 1.95 M | |||
| Total Asset | 124.52 K | |||
| Z Score | -8.4 | |||
| Net Asset | 124.52 K |
About Nexien Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nexien Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nexien Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nexien Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Nexien Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nexien Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nexien Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against Nexien Pink Sheet
The ability to find closely correlated positions to Nexien Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nexien Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nexien Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nexien Biopharma to buy it.
The correlation of Nexien Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nexien Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nexien Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nexien Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Nexien Pink Sheet
Nexien Biopharma financial ratios help investors to determine whether Nexien Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nexien with respect to the benefits of owning Nexien Biopharma security.